Madubuike Ezeibe, a research professor of veterinary medicine at Michael Okpara University of Agriculture (MOUAU), Abia state, has invented a drug he believes can cure HIV/AIDS.


Following his discovery, Ezeibe has called on the federal government to carry out a clinical trial of the drug, aluminum-magnesium silicate (AMS).

A clinical trial is a study that explores whether a medical strategy, treatment, or device is safe and effective for humans. It shows which medical approaches work best for certain illnesses or groups of people.

Ezeibe said he had on May 2, 2016, presented a paper on the potential of the drug as both antiviral and raw material, at a world conference on Ethnopharmacology in Chicago, US.


According to him, over one year after he invented and presented his findings at different international conferences, no authority anywhere in the world had disputed the research findings.

“The particles of AMS are positively and negatively charged, while HIV-infected cells are positively charged,” Ezeibe said.

“The AMS are immune stimulants; one can use simple sugar (glucose) to transport charged molecules across the mucus membrane to the blood.


“Glucose helps to transport the drug to any part of the body, including ‘the sanctuary’, where other drugs cannot reach to attack the HIV-infected cells.

“So, if these findings are true and nobody has challenged the claims of the research, let the federal government set up an inter-ministerial committee to conduct clinical trial of the medicine.

“I therefore appeal to the federal government to institute an inter-ministerial committee to carry out clinical trial of the drug in six centres across the country without further delay.

“The committee should comprise federal ministries of health, education, environment as well as science and technology, with, at least, 1000 sample patients from each state of the federation.”


Copyright 2022 TheCable. All rights reserved. This material, and other digital content on this website, may not be reproduced, published, broadcast, rewritten or redistributed in whole or in part without prior express written permission from TheCable.

Follow us on twitter @Thecablestyle